News

NICE issues new draft guidelines for end of life care

The National Institute for Health and Care Excellence (NICE) has issued draft guidelines for consultation to improve the care of adults during the last few days of life. The guidelines are meant to replace the Liverpool Care Pathway which were phased out in 2014. Key recommendations highlight the importance of communication and shared decision-making involving…

Details

Publication of revised International Staging System for myeloma

The International Myeloma Working Group (IMWG) has revised the International Staging System (ISS) to enable better stratification of newly diagnosed myeloma patients. It now includes the detection of chromosomal abnormalities (CA) by interphase fluorescent in situ hybridisation (iFISH) and the measurement of serum lactate dehydrogenase (LDH) which, when combined with the previous ISS, provides powerful…

Details

Publication of review on the management of spinal myeloma disease

Myeloma UK and the UK Spinal Myeloma Working Group have jointly published a paper on the optimal management of spinal disease in myeloma patients. Published in the British Journal of Haematology, the article provides an overview of the treatment and management options for spinal myeloma disease and highlights the role of defined pathways to enable the…

Details

Results of Cancer Drugs Fund’s list reassessment announced

The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…

Details

Updated UK guideline for the diagnosis and management of myeloma

The British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) Guideline for the Diagnosis and Management of Myeloma has recently been updated. Originally published in 2011, the latest changes to the guideline include the following recommendations: cytogenetic analysis should be performed in all patients at diagnosis; a second autologous stem…

Details